Harry Malech

Harry Malech is currently chief of the Laboratory of Host Defenses (LHD) at the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID). His research and clinical program within LHD is the Genetic Immunotherapy Section (GIS), where he focuses on development of gene therapy and hematopoietic stem cell transplantation approaches. He has overseen clinical trials of gene therapies that use ex vivo transduction of autologous hematopoietic stem cells, as well as studies of allogeneic HSC transplantation for rare diseases. Harry has authored nearly 500 peer-reviewed publications and been cited over 22,000 times.

Harry received his medical degree from Yale University in New Haven, Connecticut. He completed clinical residency training at the University of Pennsylvania in Philadelphia, followed by postdoctoral fellowship training at the NIH in Bethesda, Maryland. After completing clinical fellowship training in infectious diseases at Yale University, he remained at Yale as assistant and then associate professor and later returned to NIH as a senior investigator in NIAID.